Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.76 |
| ▸ | NPC1 | O15118 | 11/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18132519 | 0.88 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL17740292 | 0.81 | L3MBTL1 (0.72) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL21657710 | 0.81 | HIF1A (1.00) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL11926732 | 0.80 | ALDH1A1 (0.73) | RAB9ANPC1SMN1; SMN2HIF1AEPAS1 | |
| SCHEMBL21024443 | 0.80 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL28648364 | 0.80 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31072327 | 0.79 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31072328 | 0.79 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31072329 | 0.79 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL15932601 | 0.78 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333387-A1 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | GEN1E LIFESCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025226445-A1 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | GEN1E LIFESCIENCES INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025226445-A1 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | GEN1E LIFESCIENCES INC. (US) | 2025-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333387-A1 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | UACA, MYOC, LPXN | RAB9A 1438/4885NPC1 124/4885SMN1; SMN2 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.